另外值得关注的是，公司创始人、董事长宫如璟女士近日获聘香港城市大学数码医学研究院顾问委员会 成员，将作为连接产业实践与学术研究的关键桥梁角色，促进产学研融合向更高层次、更实质性的阶段 迈进，为行业创新生态构建注入新动能。 智通财经APP获悉，12月16日，医渡科技(02158)发布公告显示，当日以每股4.94港元的价格回购约64万 股，回购金额约320万港元。12月以来，公司已回购8次，累计回购约275万股，总金额约1400万港元。 密集回购背后，是公司对自身价值的坚定认可，更依托业绩改善与业务拓展的双重支撑。医渡科技2026 财年中期业绩盈利质量与运营效率实现关键突破，现有业务经调整EBITDA约5400万元，较去年同期翻 倍，会计报表层面几近盈亏平衡。 光大证券在跟踪研报中指出，公司近期在AI医疗创新落地方面取得多项进展，包括深度参与北京市医 疗领域国家人工智能应用中试基地、中标III期临床研究项目、新增河北和广州两地"惠民保"业务。报告 认为，其医疗大模型已初步构建"数据-算法-场景"闭环，推动业务在多场景中持续落地。 ...

临床上3.0T磁共振设备的磁场强度相当于地球磁场的6万倍，在磁共振环境中做手术是世界性难题。如今，来自南 开大学的交叉学科团队，正在将这一科幻电影场景变为现实。他们研发的"核磁兼容脑神经穿刺手术机器人"，能 够在术中磁共振成像（iMRI）系统的实时导航下，操控手术器械以亚毫米级的精度，穿越复杂脑组织，直达病灶 所在。这意味着医生能在手术过程中借助实时的脑区"地图"，动态避开重要功能区和血管结构，让患者的治疗更 彻底、损伤更小。在生命禁区上演的这场的"舞蹈"中，每一毫米的推进都关乎着生命…… ...

Group 1 - Beijing Weisi Weixiang Medical Technology Co., Ltd. has been established with a registered capital of 15 million yuan [1] - The legal representative of the company is Li Tao [1] - The business scope includes sales of service consumer robots, research and development of intelligent robots, manufacturing of service consumer robots, and manufacturing of special operation robots [1] Group 2 - The company is wholly owned by MicroPort Robotics-B [1]

Group 1 - The Shanghai Composite Index has reached the 4000-point mark in October 2023, indicating a significant boost in market confidence and a new level of adaptability between China's capital market and technological innovation [1] - The current market rally is characterized by structural features, driven by "policy foundation, technological empowerment, and capital resonance," with technology being the core engine of this growth [1] - The dual empowerment mechanism has matured, with reforms in the Sci-Tech Innovation Board and the Growth Enterprise Market facilitating financing for hard-tech companies, directing capital towards key areas like AI computing power and semiconductors [1] Group 2 - The "Tech Bull" market is driven by multiple factors, with technology playing a central role, supported by national policies, funding, and domestic demand stimulation [4] - Capital markets are crucial for the development of technology, as tech companies often do not generate stable cash flows initially, making venture capital (VC) a vital funding source [5] - The current environment requires a positive cycle between capital markets and technology development, with the recent reintroduction of the fifth set of standards for the Sci-Tech Innovation Board seen as a positive signal [4][5] Group 3 - Equity financing, including VC and private equity (PE), is a mature model in China, characterized by risk-sharing and no rigid repayment requirements, making it an effective way for startups to secure funding [5] - Challenges such as slow commercialization and profitability in tech companies may lead to capital withdrawal, but this is viewed as a normal market phenomenon where investors seek better-performing companies [6] - The supply mechanism for "patient capital" needs improvement, particularly in the context of VC and PE, which are currently the main forms supporting innovation [7] Group 4 - Future investment opportunities are expected in AI across all sectors, especially in embodied intelligence, which is anticipated to play a significant role in the physical world [8] - Other promising areas include the integration of AI with healthcare, resulting in smart medical devices and robotics, as well as applications in cell gene technology and low-altitude economy [8]

Core Viewpoint - The company, Suzhou Mediston Medical Technology Co., Ltd., has decided to cancel its supervisory board and amend its articles of association, along with revising and adding internal management systems to enhance corporate governance and operational efficiency [2][4]. Group 1: Cancellation of Supervisory Board - The company plans to abolish the supervisory board and transfer its responsibilities to the audit committee of the board of directors, in compliance with relevant laws and regulations [2][4]. - The supervisory board will continue to fulfill its supervisory duties until the shareholders' meeting approves the cancellation [2][3]. Group 2: Amendment of Articles of Association - The company intends to revise its articles of association to improve governance and operational standards, aligning with legal requirements and the company's actual situation [2][4]. - The proposed amendments will be submitted for approval at the shareholders' meeting and require registration with the relevant authorities [3]. Group 3: Internal Management System Revisions - The company will abolish the "Rules of Procedure for Supervisory Meetings" and introduce new systems, including the "Compensation Management System for Directors and Senior Management" and the "Information Disclosure Management System" [4][5]. - Several internal management systems have been reviewed and approved by relevant committees within the board of directors [5].

根据北交所最新披露的信息，2025年12月12日，江苏爱舍伦医疗科技集团股份有限公司IPO的状态从提 交注册变更为注册。 根据北交所最新披露的信息，2025年12月12日，江苏爱舍伦医疗科技集团股份有限公司IPO的状态从提 交注册变更为注册。 ...

Group 1 - The forum "Opportunities and Challenges for Chinese Capital Going Global" highlighted the necessity of systematic support for capital outflow, including regulations, services, and capabilities [1] - The Lingang New Area has introduced nearly 200 institutional innovations in six years, with about half being national firsts, establishing a solid foundation for financial openness and cross-border capital flow [1] - The Shanghai International Financial Center is transitioning from building a system to enhancing functionality under the guidance of the central government's strategy for a strong financial nation [1] Group 2 - The global economy shows signs of recovery driven by trade resilience, investment demand, and certain countries' policy environments, but risks from high valuation market volatility and uncertainties in international capital flows remain [2] - Innovation is identified as the core competitiveness for medical technology companies going global, necessitating international technical standards and cross-border financing support [2] - The demand for cross-border cold chain services is significantly increasing with the acceleration of innovative drugs going abroad, making technical standards and international certification crucial for service export [2] Group 3 - Financial institutions need to provide comprehensive services covering the entire lifecycle of enterprises as the types of companies going global diversify [3] - Companies must proactively identify sensitive areas and adhere to higher compliance standards due to rapidly changing hard rules regarding data cross-border and foreign investment reviews [3]

Core Viewpoint - The Hong Kong stock market is experiencing a new wave of share buybacks, with significant participation from leading technology companies, particularly in the healthcare sector [1][2]. Group 1: Share Buyback Activity - In November, companies listed on the Hong Kong stock market repurchased over 700 million shares, with over 300 million shares repurchased in just the first few trading days of December [1]. - Medical technology company Yidu Tech (02158) has been a prominent player in this buyback trend, repurchasing 155,000 shares at HKD 5.1 per share on December 12, totaling approximately HKD 790,000 [1]. - Yidu Tech has conducted seven buybacks in December, accumulating around 2.11 million shares repurchased, with a total expenditure exceeding HKD 10.8 million [1]. Group 2: Company Performance and Developments - Yidu Tech's buyback activity reflects the company's strong recognition of its own value, supported by improved performance and business expansion [1]. - For the fiscal year 2026, Yidu Tech reported a significant improvement in profitability and operational efficiency, with adjusted EBITDA reaching approximately HKD 54 million, doubling compared to the same period last year [1]. - The company is making strides in AI healthcare innovation, participating in national AI application pilot projects in Beijing and winning bids for clinical research projects, as well as expanding its "Hui Min Bao" business in Hebei and Guangzhou [1].

Core Viewpoint - Yidu Tech (02158) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 155,000 shares at a total cost of HKD 790,700 [1] - The buyback price per share ranges from HKD 5.09 to HKD 5.11 [1]

Core Insights - The 2025 Medical Value Healthcare Conference and the 6th Taishan Award Ceremony were recently held in Shanghai, focusing on the theme of "AI-driven diagnostic transformation and industry integration" [1] - JD Health showcased its breakthrough achievements in the medical AI field, particularly through its "Jingyi Qianxun" medical model, which emphasizes collaborative innovation and aims to address the challenges of medical accessibility [1] Group 1: Technological Advancements - "Jingyi Qianxun" has achieved comprehensive integration of information from text to imaging, enabling precise extraction of key information from medical records and orders, and constructing complete health profiles [2] - The model demonstrates advanced pixel-level image analysis capabilities, accurately identifying anatomical structures or lesions in medical images, including MRI, endoscopy, and ultrasound [2] - The multi-modal reasoning ability of "Jingyi Qianxun" simulates human diagnostic logic, allowing for reliable diagnostic outputs even from complex medical test results [2] Group 2: Performance Metrics - In authoritative assessments, "Jingyi Qianxun" has shown outstanding performance, achieving 99% in medical calculation ability, 91% in medical Q&A ability, and 91% in text summarization ability, placing it at the forefront of the industry [2] - The model has been validated against a comprehensive evaluation set based on clinical task data from JD Internet Hospital, confirming its leading capabilities in core medical functions [2] Group 3: Future Directions - "Jingyi Qianxun" has evolved from a general base model to a comprehensive model and then to specialized models for specific diseases, reflecting JD Health's long-term commitment to specialized fields [3] - The company plans to continue developing specialized models through technological innovation to enhance medical accessibility, professionalism, and efficiency, aiming to extend quality medical resources to a broader population [3]